FDA gives go-ahead for trial testing CAR T-cell therapy for progressive MS
According to Abelzeta, the study's first part will enroll as many as two dozen people with […]
Useful takeaways from this story.
According to Abelzeta, the study's first part will enroll as many as two dozen people with […]
Food and Drug Administration (FDA) has given Abelzeta Pharma the go-ahead to launch an early-stage clinical trial to test its CAR T-cell therapy candidate for multiple sclerosis (MS) in people with...
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
According to Abelzeta, the study's first part will enroll as many as two dozen people with […] Food and Drug Administration (FDA) has given Abelzeta Pharma the go-ahead to launch an early-stage clinical trial to test its CAR T-cell therapy candidate for multiple sclerosis (MS) in people with hard-to-treat, progressive forms of the disease.
Details worth keeping
Food and Drug Administration (FDA) has given Abelzeta Pharma the go-ahead to launch an early-stage clinical trial to test its CAR T-cell therapy candidate for multiple sclerosis (MS) in people with hard-to-treat, progressive forms of the disease.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.